Diagnosing Sepsis in Minutes
Sepsis is a healthcare condition with âincredible unmet need,â Ajay Shah, cofounder and CEO of Cytovale, tells MD+DI. âMore people die from sepsis than from breast cancer, prostate cancer, and AIDS combined each year, and it costs more than $20 billion a year to treat sepsis in the United States.â Complicating matters is that sepsis âis challenging to diagnose early in the emergency department,â he added.
Cytovale is hoping to tackle sepsis through early diagnosis. The company is developing a diagnostic test that could be used âclose to careâ to ârapidly diagnose sepsis in minutes,â said Shah. The technology is based on microfluidics research by Cytovale cofounder and scientific advisor Dino Di Carlo performed in UCLAâs bioengineering department (where he serves as professor and runs the Di Carlo Lab) and by fellow cofounder and CTO Henry Tse. Cytovaleâs core platform uses microfluidics, ultrahigh-speed imaging, computer-based vision, and machine learning to measure the biomechanical properties of thousands of individual cells.
To help Cytovale further develop the platform, the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Respons...
Source: MDDI - Category: Medical Devices Authors: Daphne Allen Tags: IVD Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Computers | Department of Health | Emergency Medicine | Funding | HIV AIDS | Learning | Medical Devices | Prostate Cancer | Study | Universities & Medical Training | USA Health